ArticleCurrent trends in immunology2025
Rebalancing immunity: The emerging role of selective estrogen receptor modulators in immunity and autoimmunity.
Article in Current trends in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Grand challenges in sex differences in immunology: problems the field must solve before biological sex can guide clinical practice.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Selective estrogen receptor modulators (SERMs) are tissue- and context-specific regulators of estrogen receptor (ER) signaling, originally developed to treat breast cancer and osteoporosis. Increasing recognition of the roles of ERα and ERβ in modulation of immune cell development, tolerance, inflammation and antiviral defense has led to growing interest in SERMs as potential therapies for autoimmune disease. This review summarizes current mechanistic, preclinical, and clinical evidence on SERMs and related ER-directed agents across autoimmune and immune-mediated conditions. Preclinical studies demonstrated that select SERMs can generate anti-inflammatory or tissue-protective effects of endogenous estrogen without negatively impacting reproductive tissue. In inflammatory arthritis, SERMs reduced synovial inflammation, modulated Th17-associated responses, and protected against bone loss in murine models. In systemic lupus erythematosus (SLE), where estrogen signaling contributes to disease susceptibility and activity, SERMs and SERDs showed variable but encouraging findings: raloxifene improved bone mineral density without increasing lupus flares, bazedoxifene preserved trabecular bone in lupus-prone mice, and fulvestrant reduced disease activity and T-cell activation markers in a randomized trial. In multiple sclerosis, ERα-dependent mechanisms mediate estradiol's protective effects in experimental autoimmune encephalomyelitis (EAE), illustrating the broader immunologic relevance of estrogen pathways. Given the high burden of glucocorticoid exposure, premature ovarian insufficiency, and osteoporosis among individuals with autoimmune diseases, SERMs may offer dual benefit as both immunomodulatory and bone-protective agents. However, available human studies remain small and short-term. Future work should define cell-specific ER signaling in human immunity and autoimmunity, identify patient subgroups most likely to benefit, and evaluate long-term safety in adequately powered clinical trials.
Indexed as
Identifiers
42232584PMC13225871What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.